Immunology and Microbiology
T Cell
100%
Epstein Barr Virus
67%
Cytotoxic T Cell
50%
Hematopoietic Stem Cell Transplantation
27%
Immunotherapy
26%
Virus
25%
Viral Disease
19%
Cytomegalovirus
17%
Adoptive Immunotherapy
15%
Bone Marrow Transplantation
15%
Chimeric Antigen Receptor
15%
Hematopoietic Cell
14%
Adenoviridae
14%
Chimeric Antigen Receptor T-Cell
13%
Graft-Versus-Host Disease
13%
Stem Cell Transplantation
12%
B Cell
11%
T Cell Receptor
11%
Lymphoproliferative Disorders
11%
CD19
10%
Interleukin 2
10%
Antineoplastic Activity
10%
Immunity
9%
Conditioning
9%
Cytokine
8%
Alemtuzumab
8%
Tumor Antigen
8%
Allogeneic Hematopoietic Stem Cell Transplantation
8%
Myeloid
8%
Stem Cell Transplant
7%
Lymphocyte
6%
Stem Cell
6%
Tumor Cell
6%
Adoptive Immunity
5%
Cyclophosphamide
5%
Overall Survival
5%
Antigen Specificity
5%
Allogeneic Bone Marrow Transplantation
5%
CD8
5%
Medicine and Dentistry
T Cell
72%
Epstein Barr Virus
46%
Cytotoxic T-Cell
30%
Cell Therapy
27%
Transplantation
26%
Diseases
22%
Hematopoietic Stem Cell Transplantation
20%
Cancer
20%
Immunotherapy
17%
Chimeric Antigen Receptor T-Cell
16%
Hematopoietic Cell
15%
Neoplasm
15%
Virus
15%
Infusion
14%
Virus Infection
13%
Lymphoproliferative Disease
13%
Pediatrics
12%
Hodgkin's Lymphoma
11%
B Cell
11%
Chimeric Antigen Receptor
11%
Adoptive Immunotherapy
9%
Hematologic Malignancy
9%
Stem Cell Therapy
9%
Tumor Antigen
9%
Cytomegalovirus
9%
Leukemia
8%
Graft Versus Host Reaction
8%
Posttransplant Lymphoproliferative Disease
8%
Immunity
8%
T Lymphocyte
7%
Acute Lymphoblastic Leukemia
7%
Allogeneic Hematopoietic Stem Cell Transplantation
7%
Bone Marrow Transplantation
7%
Effector Cell
6%
Clinical Trial
6%
Epstein-Barr Virus Infection
6%
Allogenic Bone Marrow Transplantation
6%
Adoptive Transfer
5%
Antigen Specificity
5%
Cancer Growth Factor
5%
Infection
5%
Adenoviridae
5%
Pediatrics Patient
5%
Tumor Cell
5%
Keyphrases
T Cells
27%
Epstein-Barr Virus
20%
Adoptive Cell Therapy
13%
Chimeric Antigen Receptor T Cells (CAR-T)
11%
Lymphoma
10%
Adoptive Immunotherapy
10%
Virus-specific T Cells
8%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
7%
Viral Infection
7%
Post-transplant Lymphoproliferative Disorder
6%
Donor-derived
6%
Antitumor Activity
6%
Tumor
6%
Allogeneic Bone Marrow Transplantation
6%
Adoptive Transfer
6%
Malignancy
5%
Specific T Cells
5%
Virus-specific
5%
Hematopoietic Stem Cell Transplantation
5%
Tumor Cells
5%
Tumor Antigen
5%
Genetic Modification
5%
Lymphoproliferative Disorders
5%